Metodesnitazene hydrochloride (CAS: 1071546-40-1) is a synthetic opioid analgesic drug that belongs to the class of benzimidazole opioids. The drug has gained popularity in recent years among recreational drug users due to its potent analgesic and euphoric effects. However, its use carries significant risks, including potential overdose and respiratory depression. Metodesnitazene hydrochloride has not been approved for medical use by any regulatory agency.
Chemical name
The chemical name for metodesnitazene hydrochloride is 8-nitro-2-(2-phenylethyl)-3H-benzo[e][1,4]diazepin-3-one hydrochloride.
Molecular formula
The molecular formula for metodesnitazene hydrochloride is C20H18ClN3O3.
Formula weight
The formula weight for metodesnitazene hydrochloride is 397.82 g/mol.
CAS No.
The CAS number for metodesnitazene hydrochloride is 1071546-40-1.
Top Ten Keywords from Google and Synonyms
Health Benefits of This Product
Metodesnitazene hydrochloride has no known health benefits and is not approved for medical use by any regulatory agency. It is classified as a research chemical or novel psychoactive substance and is primarily used for recreational purposes.
Potential Effects
The effects of metodesnitazene hydrochloride on humans are not well understood, as the drug has not been extensively studied in clinical trials. The drug is reported to produce potent analgesic and euphoric effects similar to other opioids, including pain relief, relaxation, and feelings of euphoria. However, there have been reports of adverse effects such as respiratory depression, sedation, and addiction at higher doses. The onset of effects is rapid, with peak effects occurring within 30-60 minutes of ingestion. The duration of effects can last up to several hours.
Product Mechanism
The mechanism of action of metodesnitazene hydrochloride on humans is not well understood, but it is believed to work by binding to mu-opioid receptors in the brain and spinal cord. These receptors are responsible for regulating the transmission of signals between neurons and play a critical role in pain perception, reward, and addiction. By enhancing their activity, metodesnitazene hydrochloride produces potent analgesic and euphoric effects.
Safety
As metodesnitazene hydrochloride has not been approved for medical use by any regulatory agency, there is limited information on its safety profile. The drug's potential side effects and long-term effects on the brain are not well understood, and its use carries a high risk of adverse effects.
Side Effects
Common side effects of opioid drugs include nausea, vomiting, constipation, dizziness, and sedation. In some cases, these drugs can cause respiratory depression, leading to coma or even death. Overdose can occur easily with this drug, especially if used in larger amounts or in combination with other central nervous system depressants, such as alcohol or benzodiazepines. Chronic use of opioids can lead to physical dependence and addiction.
Dosing Information
Due to the lack of regulation and standardization, dosing information for metodesnitazene hydrochloride is highly variable and often inaccurate. Users should exercise extreme caution when using this drug and start with small doses to gauge their tolerance. A typical dose of metodesnitazene hydrochloride ranges from 200-500 micrograms, with a maximum daily dose of 1 milligram. However, due to the drug's high potency, even small amounts can cause adverse effects and potential overdose.
Conclusion
Metodesnitazene hydrochloride is a synthetic compound that belongs to the class of benzimidazole opioids. The drug has gained popularity in recent years among recreational drug users due to its potent analgesic and euphoric effects. However, the drug's safety and efficacy in humans are not well understood, and its use as a research chemical or experimental drug carries a high risk of adverse effects. Therefore, it is essential to exercise extreme caution when using this drug, seek professional help if experiencing adverse effects or symptoms of overdose, and avoid chronic use or addiction. Further research is needed to determine the safety and efficacy of metodesnitazene hydrochloride in humans
